Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125810462 | 12581046 | 2 | F | 201512 | 20160713 | 20160721 | 20160728 | EXP | JP-INCYTE CORPORATION-2016IN004348 | INCYTE | 0.00 | E | F | Y | 37.00000 | KG | 20160728 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125810462 | 12581046 | 1 | PS | JAKAFI | RUXOLITINIB | 1 | Oral | 5 MG, BID | 202192 | 5 | MG | TABLET | |||||||
| 125810462 | 12581046 | 2 | SS | JAKAFI | RUXOLITINIB | 1 | Oral | 5 MG, UNK | 202192 | TABLET | |||||||||
| 125810462 | 12581046 | 3 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 5 MG, QD | 0 | 5 | MG | ||||||||
| 125810462 | 12581046 | 4 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 10 MG, UNK | 0 | ||||||||||
| 125810462 | 12581046 | 5 | C | FEBUXOSTAT. | FEBUXOSTAT | 1 | Oral | 40 MG, QD | 0 | 40 | MG | TABLET | |||||||
| 125810462 | 12581046 | 6 | C | FEBUXOSTAT. | FEBUXOSTAT | 1 | Oral | 40 MG, QD | 0 | 40 | MG | TABLET | |||||||
| 125810462 | 12581046 | 7 | C | TORASEMIDE | TORSEMIDE | 1 | Oral | 4 MG, QD | 0 | 4 | MG | ||||||||
| 125810462 | 12581046 | 8 | C | TORASEMIDE | TORSEMIDE | 1 | Oral | 4 MG, QD | 0 | 4 | MG | ||||||||
| 125810462 | 12581046 | 9 | C | ESOMEPRAZOLE | ESOMEPRAZOLE | 1 | Oral | 20 MG, QD | 0 | 20 | MG | ||||||||
| 125810462 | 12581046 | 10 | C | ESOMEPRAZOLE | ESOMEPRAZOLE | 1 | Oral | 20 MG, QD | 0 | 20 | MG | ||||||||
| 125810462 | 12581046 | 11 | C | FENTANYL CITRATE. | FENTANYL CITRATE | 1 | Transdermal | 1 MG, QD | 0 | 1 | MG | ||||||||
| 125810462 | 12581046 | 12 | C | FENTANYL CITRATE. | FENTANYL CITRATE | 1 | Transdermal | 1 MG, QD | 0 | 1 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125810462 | 12581046 | 1 | Myelofibrosis |
| 125810462 | 12581046 | 3 | Product used for unknown indication |
| 125810462 | 12581046 | 5 | Product used for unknown indication |
| 125810462 | 12581046 | 7 | Product used for unknown indication |
| 125810462 | 12581046 | 9 | Product used for unknown indication |
| 125810462 | 12581046 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125810462 | 12581046 | DE |
| 125810462 | 12581046 | OT |
| 125810462 | 12581046 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125810462 | 12581046 | Activated partial thromboplastin time prolonged | |
| 125810462 | 12581046 | Acute kidney injury | |
| 125810462 | 12581046 | Blood lactate dehydrogenase increased | |
| 125810462 | 12581046 | Contusion | |
| 125810462 | 12581046 | Haemarthrosis | |
| 125810462 | 12581046 | International normalised ratio increased | |
| 125810462 | 12581046 | Necrotising fasciitis | |
| 125810462 | 12581046 | Platelet count decreased | |
| 125810462 | 12581046 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125810462 | 12581046 | 1 | 201410 | 0 |